Renalytix (LON:RENX) Shares Down 10% – Here’s What Happened

Renalytix Plc (LON:RENX)’s stock price was down 10% during trading on Tuesday . The stock traded as low as GBX 1.60 and last traded at GBX 1.80. Approximately 8,739 shares traded hands during trading, a decline of 99% from the average daily volume of 1,059,987 shares. The stock had previously closed at GBX 2.

Renalytix Stock Performance

The company has a quick ratio of 2.42, a current ratio of 1.21 and a debt-to-equity ratio of -118.57. The firm has a 50-day moving average price of GBX 2.46 and a two-hundred day moving average price of GBX 4.97. The firm has a market cap of £8.74 million, a PE ratio of -0.50 and a beta of 1.97.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).